AGTX
Agentix Corp.
$0.02
+0.00 (+0.00%)
At close · Jul 3
Going-concern doubt
— flagged Jul 1, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about our ability to continue as a going concern.”View the 10-K filed Jul 1, 2026
Market Cap
$801,339
Shares
40,066,951
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.02
Open$0.02
Day$0.02–0.02
52W$0.01–0.06
Avg vol 30d19K
Short int13 · 0.0% float · 1000.0d
Short vol57%
DataJan 2020–Jul 2026
Filing10-K · Jul 1
Equibles Rating
blended score · not investment advice
Overall
Sell
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−50% below
−
Price vs 50-day avg
−28% below
◦
RSI (14)
42 · neutral
+
MACD trend
positive
−
52-week position
14% · near low
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $0 › 200d $0 — 200d above 50d
◦
Institutional flow
No 13F holder data
◦
Insider flow
No net insider activity over 90 days
◦
Short interest
0.00% of float · ▬ 0.0% MoM · 1000.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
No 13F holder history
Fundamentals
Poor
−
Revenue growth
−100% Y/Y
◦
EPS growth
0% Y/Y
−
Free cash flow
$-109.9K
−
Balance sheet
net debt $84.2K
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ2-27 quarter ends
~Sep 30, 2026
Est
filed Jul 1, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−50% below
Bearish
Price vs 50-day avg
−28% below
Bearish
RSI (14)
42 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
14% · near low
Bearish
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
52-wk low $0
Now $0 · 14%
52-wk high $0
vs 200-day avg -50%
vs 50-day avg -28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AGTX
this stock
Agentix Corp.
|
$801,339 | -46.7% | -100.0% | — | 0.0% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AGTX | -5.2% | -4.8% | -59.9% | +0.0% | -46.7% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -6.6% | -3.5% | -67.9% | +0.3% | -55.9% |